ARTICLE | Clinical News
IMP321: Phase I started
February 1, 2016 8:00 AM UTC
Prima BioMed began the open-label, dose-escalation, Australian Phase I TACTI-mel trial to evaluate IMP321 in combination with Keytruda pembrolizumab in up to 24 patients. ...